Antipsychotic Use Quality Measure and F-Tag 758 Survey Risk in LTC

The 2025 consolidation of F758 into F605 and the expansion of the antipsychotic quality measure have raised two distinct compliance risks for LTC facilities. Surveyors now check unnecessary psychotropic use as part of residents’ rights, while claims data show use that MDS reporting alone missed. Managing that exposure requires chart-level evidence of clinical need, resident consent, and ongoing monitoring.

Why F758 no longer exists as a standalone tag and what F605 now covers

On April 28, 2025, CMS folded F758 into F605, so unnecessary psychotropic medication use now falls under the chemical restraint tag. CMS stated its intent in QSO-25-07-NH as to “streamline the survey process, increase consistency, and strengthen our message that facilities must prevent the unnecessary use of psychotropic medications.” The revised QSO-25-14-NH guidance replaced that earlier memorandum. F758 is no longer a standalone citation pathway.

Under F605, a chemical restraint is any drug used for discipline or staff convenience and not required to treat medical symptoms. The definition of convenience now includes medication-induced sedation that makes it easier for staff to meet residents’ needs. At the same time, F757 was narrowed to non-psychotropic medications, removing that parallel pathway for psychotropic citations.

What surveyors are now instructed to investigate under F605

The revised Appendix PP gives surveyors an expanded critical element pathway covering indication, consent, PRN limits, gradual dose reduction, and physician oversight. Prescribing is only the starting point for review. Each psychotropic must have a specific, diagnosed, documented condition supporting its use, and a defensible clinical decision does not excuse missing process documentation. Before initiation or a dose increase, the resident must be notified and have the right to accept or decline. Surveyors check the consent documentation for that decision.

F658 directs surveyors to investigate diagnoses made without sufficient supporting documentation, including conditions for which antipsychotics have an approved indication. F841 makes the medical director’s responsibility for practitioner adherence to diagnosis and prescribing policies an explicit inspection target. These requirements connect the resident’s chart to facility oversight rather than treating prescribing as an isolated decision.

PRN orders create a separate route to noncompliance. All PRN psychotropics must treat a specific, diagnosed, documented condition and are subject to a 14-day limit. Hospice patients are not exempt from these requirements. Surveyors also examine functional substitution, including use of valproic acid, oxcarbazepine, diphenhydramine, or hydroxyzine in place of psychotropics for purposes outside their original approved indications. When those medications are used this way, the psychotropic requirements apply to them.

The three documentation failures that drive most antipsychotic citations

Antipsychotics were the most cited drug category under F758, with recurring failures centered on behavioral monitoring, PRN order discipline, and gradual dose reduction, or GDR. The first failure is an incomplete account of the symptoms being treated. A standing order does not establish that behaviors were assessed, tracked, and linked to medication use. For example, a resident may arrive from a hospital with an antipsychotic on the medication reconciliation list. If the indication is not re-documented in the SNF chart, the receiving facility owns that gap despite not having initiated treatment.

The second failure is allowing PRN antipsychotic orders to pass the 14-day limit or renewing them without a documented physician evaluation. The third is incomplete GDR scheduling or documentation. GDR attempts are required in two separate quarters during the first year, at least one month apart, and annually thereafter. The chart must record the outcome or a clear, physician-signed clinical rationale for contraindication.

CMS expects the QAPI process to catch these deficiencies before survey. That requires policies addressing clinical diagnosis, medication errors, monitoring programs, and pharmacist-PCP coordination. A facility can have a clinically justified prescription but still lack the evidence needed to demonstrate compliant care. Under F605, that documentation failure connects directly to a residents’ rights violation, increasing severity exposure compared with the former F758 pathway.

How the expanded antipsychotic quality measure is pushing reported rates higher

The Long-Stay Antipsychotic Quality Measure introduces a separate pressure through its conversion from MDS-only reporting to a hybrid methodology. It now incorporates Medicare and Medicaid claims and Medicare Advantage encounter data. The purpose is to capture antipsychotic use previously invisible in MDS reporting. Consequently, broader capture can produce a higher reported rate with prescribing behavior unchanged. That distinction is essential when facilities interpret their dashboards.

The measurement window explains how the increase occurs. Under the prior method, a medication filled outside the 7-day MDS look-back window would not be captured. Under the hybrid method, a prescription filled during the target period triggers the measure even if it was not administered during that period. CMS anticipated higher reported rates from this methodological change. Those expectations are projections.

Exclusion rules also affect the reported result. Documented industry criticism has focused on the criteria used to exclude residents with schizophrenia, and the specifications have required correction. An April 2026 revision addressed a calculation inconsistency that had failed to appropriately exclude a subset of residents with schizophrenia from the January 2026 data release. The lesson for facilities is to track specification updates as well as rates.

How Five-Star ratings and payment reductions attach to the quality measure

Failure to respond to a schizophrenia audit request results in a payment reduction. Failure of the audit itself can reduce the long-stay quality measure domain to one star for six months and suppress the long-stay antipsychotic quality measure for 12 months. These are distinct consequences tied to audit response and substantiation, whose application requires more than an increase in a facility’s rate.

Suppression also creates a public reporting problem. Removing the measure does not remove the reputational exposure, because it signals to consumers and referral sources that the facility could not substantiate its exclusion claims. The enforcement history predates the hybrid methodology. CMS identified facilities with no improvement in antipsychotic utilization since 2011 as “late adopters” and subjected a subset with repeated noncompliance citations to enhanced oversight. QSO-19-07-NH described that approach, which has since been integrated into the revised guidance.

Why the clinical risk to residents amplifies the compliance obligation

The regulatory warning identifies an increased risk of death when antipsychotics are used in elderly patients with dementia. The adverse effects extend beyond that warning. They include falls, excessive sedation, altered mental status, orthostatic hypotension, extrapyramidal symptoms, tardive dyskinesia, metabolic changes, and cardiovascular events. Harm from medication can also put a facility at risk of citations under requirements for falls, skin integrity, or quality of care.

Less conspicuous changes deserve attention as well. Loss of interest in activities, difficulty concentrating, or behavioral withdrawal may indicate medication-related deterioration in quality of life. If staff miss those changes and leave them out of the chart, the facility may miss an adverse medication outcome. Behavioral monitoring, GDR attempts, and nonpharmacological interventions first are therefore clinical protections against continued treatment whose necessity has not been reassessed. Prospective identification of residents at combined clinical and regulatory risk is a patient safety responsibility.

Identifying which residents carry the highest combined clinical and regulatory risk

The monitored population includes residents receiving antipsychotics, antidepressants, anxiolytics, and hypnotics, as well as medications used as functional psychotropic substitutes. An antipsychotic-only audit leaves part of that population unseen. For every affected resident, staff must review the indication, the records of behavior, and the GDR schedule. Within that population, prioritization depends on where clinical vulnerability and missing evidence intersect. Residents arriving with existing psychotropic prescriptions form an immediate priority because admission creates a new obligation to establish the indication in the facility’s chart.

Residents coded on the MDS with schizophrenia as an exclusion diagnosis form a separate audit-risk cohort. CMS cross-references that coding against claims data under the hybrid measure. A diagnosis asserted on the MDS but unsupported by physician encounter records, pharmacy records, or other claims sources can trigger an audit. This is a documentation risk distinct from whether the resident is experiencing an adverse effect.

For each at-risk resident, the chart must connect clinical justification to a specific diagnosis and behavioral tracking to medication use. It must also show GDR attempts or a physician-signed rationale for contraindication, together with monitoring for adverse reactions. Changes in function, mood, or engagement belong in that assessment. For schizophrenia exclusions, the supporting record must withstand cross-referencing against claims data. These requirements make risk stratification practical by distinguishing residents with complete evidence from those whose clinical course or documentation needs attention first.

Why manual monitoring processes cannot reliably surface these gaps at the rate surveyors now move

A spreadsheet or monthly DON report must capture required attempts, their spacing, outcomes, annual repetition, and contraindication rationale. Staff turnover, changes in MDS coordinators, or a disrupted clinical schedule can break that sequence. Monthly reporting makes the resulting gap visible only retrospectively. Across multiple buildings, reports from different DONs or pharmacies also introduce inconsistency, and staff may identify a missed window in those reports only when a survey is already scheduled.

A prescription filled at an outside pharmacy during the target period may appear in claims before the facility’s chart reflects it. Published quality improvement research in JAMDA described facilities using spreadsheet-based decision support tools to aggregate EHR data and monitor antipsychotic rates.

Nurses write what they observe in clinical notes, while medication orders and GDR records may need to be reviewed separately. To link a gradual change in engagement or function to medication use, staff need to review those records together. When that review is periodic and manual, the pattern can remain unrecognized until an adverse event or survey brings it into focus. The weakness is the interval between documentation and interpretation.

What continuous, chart-level monitoring of psychotropic medication compliance looks like in practice

Effective monitoring operates at the clinical-note level because that is where citation-generating omissions and early signs of deterioration appear. Much of the information already exists in the EHR. Every shift, nurses record behaviors, medication administration, and how residents respond, but those observations often stay in unstructured text. A working system connects that text with medication records. Its purpose is to surface incomplete evidence and approaching deadlines while there is time for clinical review.

Medication identification must include conventional psychotropics and antihistamines or anticonvulsants used as substitutes, with each resident flagged for indication-documentation completeness. Scheduling must track two GDR attempts in separate quarters of the first year, at least one month apart, and annual attempts thereafter. Alerts must precede the closing window. PRN antipsychotic monitoring must also flag orders nearing the 14-day limit that have no documented physician evaluation for renewal.

Clinical monitoring must also link changes in engagement, mood, or function to medication records so those changes can be assessed as possible adverse effects. For schizophrenia exclusions, supporting documentation must be available for a CMS audit without a manual search across multiple records. Real-time dashboards that bring together medication records, MDS Section N data, and GDR documentation can give nursing managers and a VP of Clinical a ranked view across buildings. That view supports prioritization at both resident and facility level.

The workflow must use the EHR documentation already in place so nurses do not have to enter the same information into another system. Additional documentation burden is not operationally viable in the nursing workforce described here. To keep this work going, facilities need to use the records they already have to make decisions in time, while the practitioners who care for the resident remain responsible for clinical assessment and prescribing.